Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity

Curiel, Tyler J., Wei, Shuang, Dong, Haidong, Alvarez, Xavier, Cheng, Pui, Mottram, Peter, Krzysiek, Roman, Knutson, Keith L. +14 more·2003·Nature Medicine
DOI 10.1038/nm863

Cited by (1,000)

Items 501–600 of 1,000

  1. Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view
    Humera Memon, Bhoomika M. Patel · 2019 · Life Sciences
  2. Preferential Recruitment of Th17 Cells to Cervical Cancer via CCR6-CCL20 Pathway
    Qing Yu, Xiangming Lou, Yan He · 2015 · PLoS ONE
  3. PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma
    Ke Ma, Xin Wei, Danfeng Dong, Yinying Wu, Qianqian Geng, Enxiao Li · 2017 · Oncology Letters
  4. Cancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine Milieu
    M. Colombo, Leonardo Mirandola, Maurizio Chiriva‐Internati, Andrea Basile, Massimo Locati, Elena A. Lesma, Raffaella Chiaramonte, Natalia Platonova · 2018 · Frontiers in Immunology
  5. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis
    Lianzhou Yang, Rujun Xue, Chunhua Pan · 2019 · OncoTargets and Therapy
  6. Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer
    Ching‐Yao Yang, Ming Huei Fan, Carol H. Miao, Yi‐Jen Liao, Ray‐Hwang Yuan, Chao-Lien Liu · 2020 · Molecular Therapy — Oncolytics
  7. Prognostic value of PD -L1 expression in patients with primary solid tumors
    Xiao Jun Xiang, Pengcheng Yu, Di Long, Xiao-Li Liao, Sen Zhang, Xue‐Mei You, Jian‐Hong Zhong, Lequn Li · 2017 · Oncotarget
  8. PD-L1 Glycosylation and Its Impact on Binding to Clinical Antibodies
    Július Benický, Miloslav Šanda, Zuzana Brnáková, Oliver C. Grant, Robert J. Woods, Alan L. Zwart, Radoslav Goldman · 2020 · Journal of Proteome Research
  9. ERK/p38 MAP‐kinases and PI3K are involved in the differential regulation of B7‐H1 expression in DC subsets
    Svetlana Karakhanova, Stefan Meisel, Sabine Ring, Karsten Mahnke, Alexander Enk · 2009 · European Journal of Immunology
  10. Immunotherapy opportunities in ovarian cancer
    Christina Chu, Sarah H. Kim, Carl H. June, George Coukos · 2008 · Expert Review of Anticancer Therapy
  11. Prostaglandin D2 affects the differentiation and functions of human dendritic cells: impact on the T cell response
    Philippe Gosset, Muriel Pichavant, Christelle Faveeuw, Fabrice Bureau, André‐Bernard Tonnel, François Trottein · 2005 · European Journal of Immunology
  12. Ex Vivo Expanded Hematopoietic Stem Cells Overcome the MHC Barrier in Allogeneic Transplantation
    Junke Zheng, Masato Umikawa, Shichuan Zhang, HoangDinh Huynh, Robert E. Silvany, Benjamin P.C. Chen, Lieping Chen, Cheng Cheng Zhang · 2011 · Cell stem cell
  13. Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization
    Nai-Yun Sun, Yu‐Li Chen, Wen‐Yih Wu, Han-Wei Lin, Ying‐Cheng Chiang, Chi-Fang Chang, Yi‐Jou Tai, Heng‐Cheng Hsu, Chi‐An Chen, Wei‐Zen Sun et al. · 2019 · Cancers
  14. Interferon gamma induced by resveratrol analog, HS-1793, reverses the properties of tumor associated macrophages
    Soo Kyung Jeong, Kwangmo Yang, You Soo Park, You Jin Choi, Su Jung Oh, Chan Woo Lee, Kyu Yeol Lee, Min Ho Jeong, Wol Soon Jo · 2014 · International Immunopharmacology
  15. Clinical impact of herpesvirus entry mediator expression in human hepatocellular carcinoma
    Daisuke Hokuto, Masayuki Sho, Ichiro Yamato, Satoshi Yasuda, Shinsaku Obara, Takeo Nomi, Yoshiyuki Nakajima · 2014 · European Journal of Cancer
  16. Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer
    Noffar Bar, Federica Costa, Rituparna Das, Alyssa M. Duffy, Mehmet Samur, Samuel Spence McCachren, Scott N. Gettinger, Natalia Neparidze, Terri L. Parker, Jithendra Kini Bailur et al. · 2020 · JCI Insight
  17. ADAP and SKAP55 deficiency suppresses PD‐1 expression in CD8+ cytotoxic T lymphocytes for enhanced anti‐tumor immunotherapy
    Li, Chunyang, Li, Weiyun, Xiao, Jun, Jiao, Shaozhuo, Teng, Fei, Xue, Shengjie, Zhang, Chi, Sheng, Chun, Leng, Qibin, Rudd, Christopher E et al. · 2015 · EMBO Molecular Medicine
  18. Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients
    Carlos Alfaro, José Luis Perez‐Gracia, Natalia Suárez, Javier Rodríguez, Miguel F. Sanmamed, Bruno Sangro, Salvador Martín‐Algarra, Alfonso Calvo, Miriam Redrado, Alice Agliano et al. · 2011 · The Journal of Immunology
  19. Macrophages as Promising Carriers for Nanoparticle Delivery in Anticancer Therapy
    Anna Wróblewska, Agnieszka Szczygieł, Bożena Szermer-Olearnik, Elżbieta Pajtasz‐Piasecka · 2023 · International Journal of Nanomedicine
  20. The immunosuppressive factors IL-10, TGF-β, and VEGF do not affect the antigen-presenting function of CD40-activated B cells
    Alexander Shimabukuro‐Vornhagen, Andreas Draube, Tanja M. Liebig, Achim Rothe, Matthias Kochanek, Michael S. von Bergwelt‐Baildon · 2012 · Journal of Experimental & Clinical Cancer Research
  21. Prognostic value of immune cell infiltration, tertiary lymphoid structures and PD-L1 expression in Merkel cell carcinomas.
    Daniel S. Behr, Wiebke K. Peitsch, Christian Hametner, Felix Lasitschka, Roland Houben, Kathrin Schönhaar, Julia Michel, Claudia Dollt, Matthias Goebeler, Alexander Marx et al. · 2014 · Europe PMC (PubMed Central)
  22. Epitope and Paratope Mapping of PD-1/Nivolumab by Mass Spectrometry-Based Hydrogen–Deuterium Exchange, Cross-linking, and Molecular Docking
    Mengru Mira Zhang, Richard Y.‐C. Huang, Brett R. Beno, Ekaterina G. Deyanova, Jing Li, Guodong Chen, Michael L. Gross · 2020 · Analytical Chemistry
  23. Pancreatic Ductal Adenocarcinoma: A Review of Immunologic Aspects
    Megan Wachsmann, Laurentiu M. Pop, Ellen S. Vitetta · 2012 · Journal of Investigative Medicine
  24. B7‐H1 up‐regulation impairs myeloid DC and correlates with disease progression in chronic HIV‐1 infection
    Xicheng Wang, Zheng Zhang, Shuye Zhang, Junliang Fu, Jinxia Yao, Yanmei Jiao, Hao Wu, Fu‐Sheng Wang · 2008 · European Journal of Immunology
  25. Immunotherapy for Ovarian Cancer
    Justin Michael Drerup, Liu Yang, Alvaro Souto Padron, Kruthi Murthy, Vincent J. Hurez, Bin Zhang, Tyler Jay Curiel · 2015 · Current Treatment Options in Oncology
  26. State-of-the-art of regulatory dendritic cells in cancer
    Jose Ramon Conejo-Garcia, Melanie R. Rutkowski, Juan R. Cubillos‐Ruiz · 2016 · Pharmacology & Therapeutics
  27. Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma
    Qiankun Xie, Yujie Zhao, Tao Pan, Ning Lyu, Luwen Mu, Shaolong Li, Mu-De Shi, Zhenfeng Zhang, Penghui Zhou, Ming Zhao · 2016 · OncoImmunology
  28. The transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcome
    Lotte Pyfferoen, Elisabeth Brabants, Celine Everaert, Nancy De Cabooter, Kelly Heyns, Kim Deswarte, Manon Vanheerswynghels, Sofie De Prijck, Glenn Wagemans, Mélissa Dullaers et al. · 2016 · OncoImmunology
  29. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma
    Shingo Inaguma, Jerzy P. Lasota, Zengfeng Wang, Piotr Czapiewski, Renata Langfort, Janusz Ryś, Joanna Szpor, Piotr Waloszczyk, Krzysztof Okoń, Wojciech Biernat et al. · 2017 · Human Pathology
  30. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study
    Liyang Hu, Xiaolu Xu, Hui‐Lan Rao, Jie Chen, Renchun Lai, Huiqiang Huang, Wen-Qi Jiang, Tongyu Lin, Zhongjun Xia, Qingqing Cai · 2017 · 癌症：英文版
  31. Vaccine Injection Site Matters: Qualitative and Quantitative Defects in CD8 T Cells Primed as a Function of Proximity to the Tumor in a Murine Glioma Model
    John R. Ohlfest, Brian M. Andersen, Adam J. Litterman, Junzhe Xia, Christopher A. Pennell, Lauryn E. Swier, Andres Μ. Salazar, Michael R. Olin · 2012 · The Journal of Immunology
  32. Immune Signatures of Murine and Human Cancers Reveal Unique Mechanisms of Tumor Escape and New Targets for Cancer Immunotherapy
    Rebecca E. Sadun, Suzanne M. Sachsman, Xiaoying Chen, K. Christenson, William Z. Morris, Peisheng Hu, Alan L. Epstein · 2007 · Clinical Cancer Research
  33. Dual Control of Antitumor CD8 T Cells through the Programmed Death-1/Programmed Death-Ligand 1 Pathway and Immunosuppressive CD4 T Cells: Regulation and Counterregulation
    Andrew J Currie, Amy Prosser, Alison M. McDonnell, Amanda L. Cleaver, Bruce W. S. Robinson, Gordon James Freeman, Robbert G. Van der Most · 2009 · The Journal of Immunology
  34. Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: novel cancer escaping mechanisms
    Masao, Ichikawa · 2005 · Frontiers in bioscience
  35. Immunological configuration of ovarian carcinoma: features and impact on disease outcome
    Jitka Palich Fucikova, An Coosemans, Sandra Oršulić, David Cibula, Ignace B. Vergote, Lorenzo Galluzzi, Radek Špíšek · 2021 · Journal for ImmunoTherapy of Cancer
  36. A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis
    Qizhi Ma, Xia He, Benxia Zhang, Fuchun Guo, Xuejin Ou, Qiyu Yang, Pei Shu, Yue Chen, Kai Li, Ge Gao et al. · 2022 · Signal Transduction and Targeted Therapy
  37. The increase of circulating PD-L1-expressing CD68+ macrophage in ovarian cancer
    Qiu‐Xia Qu, Qin Miao Huang, Yu Shen, Yibei Zhu, Xueguang Zhang · 2015 · Tumor Biology
  38. A Four-Factor Immunoscore System That Predicts Clinical Outcome for Stage II/III Gastric Cancer
    Ti Wen, Zhenning Wang, Yi Li, Zhi Li, Xiaofang Che, Yibo Fan, Shuo Wang, Jinglei Qu, Xianghong Yang, Kezuo Hou et al. · 2017 · Cancer Immunology Research
  39. Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells
    Rodolphe Vereecque, Aurore Saudemont, Bruno Quesnel · 2004 · Leukemia
  40. Molecular Mechanisms Underlying the Bioactive Properties of a Ketogenic Diet
    Mari Murakami, Paola Tognini · 2022 · Nutrients
  41. Single-cell transcriptome analysis of epithelial, immune, and stromal signatures and interactions in human ovarian cancer
    Chaochao Chai, Langchao Liang, Nanna S. Mikkelsen, Wei Wang, Wandong Zhao, Chengcheng Sun, Rasmus Otkjær Bak, Hanbo Li, Lin Lin, Fei Wang et al. · 2024 · Communications Biology
  42. Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer
    Francois Michel Lemoine · 2009 · International Journal of Oncology
  43. Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation
    Michael T. Spiotto, Yang‐Xin Fu, Hans Schreiber · 2003 · Current Opinion in Immunology
  44. Microenvironmental regulation in tumor progression: Interactions between cancer-associated fibroblasts and immune cells
    Dandan Gao, Liguang Fang, Cun Liu, Mengrui Yang, Xiaoyun Yu, Longyun Wang, Wen‐Feng Zhang, Changgang Sun, Jing Zhuang · 2023 · Biomedicine & Pharmacotherapy
  45. Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors
    Luciana Alexandra Pavelescu, Robert Mihai Enache, Oana Alexandra Roşu, Monica Profir, Sanda Maria Creţoiu, Bogdan Severus Gașpar · 2024 · International Journal of Molecular Sciences
  46. Roadmap to a Better Therapeutic Tumor Vaccine
    Leisha A. Emens · 2006 · International Reviews of Immunology
  47. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer
    Yunfeng Ma, Chen Chen, Dongqing Li, Min Liu, Zhuangwei Lv, Yanhong Ji, Jiru Xu · 2016 · Oncotarget
  48. Clinical implications of tumor-intrinsic mechanisms regulating PD-L1
    Alessandro Prestipino, Robert Zeiser · 2019 · Science Translational Medicine
  49. Dendritic cells and innate defense against tumor cells
    Evelyn Ullrich, Cédric Menard, Caroline Flament, Magali Terme, Grégoire Mignot, Mathieu Bonmort, Joël Plumas, Laurence Chaperot, Nathalie Chaput, Laurence Zitvogel · 2008 · Cytokine & Growth Factor Reviews
  50. Immune checkpoint inhibitors for the treatment of melanoma
    Francesco Sabbatino, Luigi Liguori, Stefano Pepe, Soldano Ferrone · 2022 · Expert Opinion on Biological Therapy
  51. Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms
    Gwenyth J. Joseph, Douglas Buckner Johnson, Rachelle W. Johnson · 2023 · Journal of bone oncology
  52. Function of PD-L1 in antitumor immunity of glioma cells
    Yongli Lou, Jin Shi, Dewei Guo, Ahmad Kaleem Qureshi, Laijun Song · 2015 · Saudi Journal of Biological Sciences
  53. Clinical Use of Programmed Cell Death-1 and Its Ligand Expression as Discriminatory and Predictive Markers in Ovarian Cancer
    Jayanta Chatterjee, Wei Dai, Nor Haslinda Abd Aziz, Pei Y. Teo, John Wahba, David L. Phelps, Christian J. Maine, Lynsey May Whilding, Roberto E. Dina, Giorgia Trevisan et al. · 2016 · Clinical Cancer Research
  54. Immunotherapy using anti-PD-1 and anti-PD-L1 in Leishmania amazonensis-infected BALB/c mice reduce parasite load
    Alessandra Marcia da Fonseca-Martins, Tadeu Diniz Ramos, Juliana Elena Silveira Pratti, Luan Firmino-Cruz, Daniel Cláudio Oliveira Gomes, Lynn Soong, Elvira M. Saraiva, Herbert Leonel de Matos Guedes · 2019 · Scientific Reports
  55. Targeting the androgen receptor to enhance NK cell killing efficacy in bladder cancer by modulating ADAR2/circ_0001005/PD-L1 signaling
    Qing Liu, Bosen You, Jialin Meng, Chi‐Ping Huang, Guanglu Dong, Ronghao Wang, Fu-Ju Chou, Shan Gao, Chawnshang Chang, Shuyuan Yeh et al. · 2022 · Cancer Gene Therapy
  56. Microenvironment of the murine mammary carcinoma 4T1: Endogenous IFN-γ affects tumor phenotype, growth, and metastasis
    Sally A. duPre', Doug D. Redelman, Kenneth W. Hunter · 2008 · Experimental and Molecular Pathology
  57. The chemotherapeutic drug oxaliplatin differentially affects blood DC function dependent on environmental cues
    Jurjen Tel, Stanleyson V. Hato, Ruurd Torensma, Sonja I. Buschow, Carl Gustav Figdor, Willem Joost Lesterhuis, I. Jolanda M. de Vries · 2011 · Cancer Immunology Immunotherapy
  58. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy
    Susumu Saigusa, Yuji Toiyama, Koji Tanaka, Yasuhiro Inoue, Koichiro Mori, Shozo Ide, Hiroki Imaoka, Mikio Kawamura, Yasuhiko Mohri, Masato Kusunoki · 2016 · International Journal of Clinical Oncology
  59. DIgR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-initiated antigen-specific T-cell responses
    Liyun Shi, Kun Luo, Dajing Xia, Taoyong Chen, Guoyou Chen, Yingming Jiang, Nan Li, Xuetao Cao · 2006 · Blood
  60. Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy
    Hassan Issafras, Shilong Fan, Chi-Ling Tseng, Yunchih Cheng, Pei-Hua Lin, Lisa Xiao, Yun-Ju Huang, Chih‐Hsiang Tu, Ya-Chin Hsiao, Min Li et al. · 2021 · PLoS ONE
  61. Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression
    Hiroaki Saito, Yusuke Kono, Yuki Murakami, Yuji Shishido, Hirohiko Kuroda, Tomoyuki Matsunaga, Yoji Fukumoto, Tomohiro Osaki, Keigo Ashida, Yoshiyuki Fujiwara · 2018 · Anticancer Research
  62. Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment
    Anna Pawłowska, Dorota Suszczyk, Karolina Okła, Bartłomiej Barczyński, Jan Kotarski, Iwona Wertel · 2018 · Clinical & Experimental Immunology
  63. The FG Loop of PD-1 Serves as a “Hotspot” for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy
    Danqing Chen, Shuguang Tan, Hao Zhang, Haiyuan Wang, Wei-Wu He, Rui Shi, Zhou Tong, Jianhua Zhu, Hao D. Cheng, Shan Gao et al. · 2019 · iScience
  64. Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines
    Alain P. Vicari, Isabelle Treilleux, Serge Lebecque · 2004 · Seminars in Cancer Biology
  65. Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation
    Ray Sagawa, Seiji Sakata, Bo Gong, Yosuke Seto, Ai Takemoto, Satoshi Takagi, Hironori Ninomiya, Noriko Yanagitani, Masayuki Nakao, Mingyon Mun et al. · 2021 · JCI Insight
  66. Immunobiology of Cancer Therapies Targeting CD137 and B7-H1/PD-1 Cosignal Pathways
    Shengdian Wang, Lieping Chen · 2010 · Current topics in microbiology and immunology
  67. Th17 cells have stem cell-like features and promote long-term immunity
    Shuang Wei, Ende Zhao, Ilona Kryczek, Weiping Zou · 2012 · OncoImmunology
  68. Proinflammatory S100A8 Induces PD-L1 Expression in Macrophages, Mediating Tumor Immune Escape
    Zhengshuo Li, Jing Wang, Xuemei Zhang, Peishan Liu, Xiaoyue Zhang, Jia Wang, Xiang Zheng, Lingyu Wei, Peng Qiu, Can Liu et al. · 2020 · The Journal of Immunology
  69. Bladder cancer cell‐intrinsic PD‐L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy
    Deyi Zhang, Ryan Michael Reyes, Erica Osta, Suresh Kari, Harshita B. Gupta, Alvaro Souto Padron, Anand V. R. Kornepati, Aravind Kancharla, Xiujie Sun, Yilun Deng et al. · 2021 · Cancer Medicine
  70. Dendritic cells: tools and targets for antitumor vaccination
    Martijn H. den Brok, Stefan Nierkens, Carl Gustav Figdor, Theo J. M. Ruers, Gosse J. Adema · 2005 · Expert Review of Vaccines
  71. Aurora A kinase inhibition compromises its antitumor efficacy by elevating PD-L1 expression
    Xiaobo Wang, Jing Huang, Fenglin Liu, Qian Yu, Ruina Wang, Jiaqi Wang, Zewen Zhu, Juan Yu, Jun Wei Hou, Joong Sup Shim et al. · 2023 · Journal of Clinical Investigation
  72. Peripheral blood gene expression of B7 and CD28 family members associated with tumor progression and microscopic lymphovascular invasion in colon cancer patients
    Hyunji Lee, Ji Hyun Kim, Sung Yeun Yang, Jihye Kong, Minkyung Oh, Dae Hoon Jeong, Jaeil Chung, Ki Beom Bae, Jin Yong Shin, Kwan Hee Hong et al. · 2010 · Journal of Cancer Research and Clinical Oncology
  73. Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance
    Gerald Willimsky, Karin Schmidt, Christoph Loddenkemper, Johanna Gellermann, Thomas J. F. Blankenstein · 2013 · Journal of Clinical Investigation
  74. Blocking of monocyte-associated B7-H1 (CD274) enhances HCV-specific T cell immunity in chronic hepatitis C infection
    Hye-Young Jeong, Youn-Jae Lee, Su‐Kil Seo, Soo-Woong Lee, Sung Jae Park, Jeong-Nyeo Lee, Hae‐Sook Sohn, Sheng Yao, Lieping Chen, Inhak Choi · 2007 · Journal of Leukocyte Biology
  75. Bridging angiogenesis and immune evasion in the hypoxic tumor microenvironment
    Luana Schito · 2018 · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
  76. Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes
    Tianshi Lu, Shidan Wang, Lin Xu, Qinbo Zhou, Nirmish Singla, Jianjun Gao, Subrata Manna, Laurentiu M. Pop, Zhiqun Xie, Mingyi Chen et al. · 2020 · Science Immunology
  77. Dendritic cell vaccine therapy for colorectal cancer
    Amanda L. McCormick, Lydia H. Girgis, Hayley S Brazeale, Trevor S. Anderson, Laurence M. Wood, Devin B. Lowe · 2020 · Pharmacological Research
  78. PD-L1 siRNA–hyaluronic acid conjugate for dual-targeted cancer immunotherapy
    Suyeon Kim, Roun Heo, Seok Ho Song, Kwon‐Ho Song, Jung Min Shin, Se Jin Oh, Hyo‐Jung Lee, Jo Eun Chung, Jae Hyung Park, Tae Woo Kim · 2022 · Journal of Controlled Release
  79. Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease
    Wu, Florence T. H., Xu, Ping, Chow, Annabelle, Man, Shan, Krüger, Janna, Khan, Kabir A., Paez-Ribes, Marta, Pham, Elizabeth, Kerbel, Robert S. · 2019 · British Journal of Cancer
  80. Paracrine signaling in cancer-associated fibroblasts: central regulators of the tumor immune microenvironment
    Ye Li, Longyun Wang, Wenzhe Ma, Jibiao Wu, Qibiao Wu, Changgang Sun · 2025 · Journal of Translational Medicine
  81. Pembrolizumab for the treatment of non-small cell lung cancer
    Mirte Muller, Robert D. Schouten, Cornedine Jannette de Gooijer, Paul Baas · 2017 · Expert Review of Anticancer Therapy
  82. B7‐H1 (CD274) inhibits the development of herpetic stromal keratitis (HSK)
    Jun Her, Su Kil Seo, Hye-Young Jeong, Hyoun-Mi Seo, Gefeng Zhu, Lieping Chen, In-Hak Choi · 2005 · FEBS Letters
  83. The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
    Ciliang Guo, Lingkai Kong, Lingjun Xiao, Kua Liu, Huawei Cui, Qilei Xin, Xiaosong Gu, Chunping Jiang, Junhua Wu · 2023 · Cell & Bioscience
  84. Langerhans Cells from Human Cutaneous Squamous Cell Carcinoma Induce Strong Type 1 Immunity
    Hideki Fujita, Mayte Suárez‐Fariñas, Hiroshi Mitsui, Juana Gonzalez, Mark J. Bluth, Shali Zhang, Diane Felsen, James G. Krueger, John A. Carucci · 2012 · Journal of Investigative Dermatology
  85. B7-DC-Ig Enhances Vaccine Effect by a Novel Mechanism Dependent on PD-1 Expression Level on T Cell Subsets
    Mikayel Mkrtichyan, Yana George Najjar, Estella C. Raulfs, Linda L. Liu, Solomon Langerman, Geoffrey C. Guittard, Laurent L. Ozbun, Samir N. Khleif · 2012 · The Journal of Immunology
  86. Increased B7-H1 Expression on Dendritic Cells Correlates with Programmed Death 1 Expression on T Cells in Simian Immunodeficiency Virus-Infected Macaques and May Contribute to T Cell Dysfunction and Disease Progression
    Huanbin Xu, Xiaolei Wang, Bapi Pahar, Terri Moroney‐Rasmussen, Xavier A. Alvarez, Andrew A. Lackner, Ronald S. Veazey · 2010 · The Journal of Immunology
  87. Considerations for successful cancer immunotherapy in aged hosts
    Vincent J. Hurez, Alvaro Souto Padron, Robert Scott Svatek, Tyler Jay Curiel · 2017 · Experimental Gerontology
  88. Hypoxia: Turning vessels into vassals of cancer immunotolerance
    Luana Schito, Sergio Rey · 2020 · Cancer Letters
  89. Tumor Vessel Normalization: A Window to Enhancing Cancer Immunotherapy
    Sai Li, Qi Zhang, Yupeng Hong · 2020 · Technology in Cancer Research & Treatment
  90. Fibroblast diversity and plasticity in the tumor microenvironment: roles in immunity and relevant therapies
    Yashi Xu, Wei Li, Shitong Lin, Binghan Liu, Peng Wu, Li Li · 2023 · Cell Communication and Signaling
  91. Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction
    Djoke Hendriks, Yuan Zhang He, Iris Koopmans, Valerie R. Wiersma, Robert J. van Ginkel, Douwe Freerk Samplonius, Wijnand Helfrich, Edwin Bremer · 2016 · OncoImmunology
  92. Anti-angiogenesis: Opening a new window for immunotherapy
    Feifei Guo, Jiuwei Cui · 2020 · Life Sciences
  93. B7-H1 up-regulation on dendritic-like leukemia cells suppresses T cell immune function through modulation of IL-10/IL-12 production and generation of Treg cells
    Ge, Wei, Ma, Xiaotong, Li, Xin, Wang, Yafei, Li, Changhong, Meng, Hengxing, Liu, Xiaofan, Yu, Zhen, You, Shengguo, Qiu, Lugui · 2009 · Leukemia Research
  94. The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy
    Keywan Mortezaee, Jamal Majidpoor, Ebrahim Kharazinejad · 2023 · Biomedicine & Pharmacotherapy
  95. Immunotherapy for advanced melanoma: Fulfilling the promise
    Helen J Gogas, Aristidis Polyzos, John M. Kirkwood · 2013 · Cancer Treatment Reviews
  96. Modification of the tumor microenvironment to enhance immunity
    Yu‐Pei Liao · 2007 · Frontiers in bioscience
  97. Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes
    Juan R. Cubillos‐Ruiz, Melanie R. Rutkowski, Jose Ramon Conejo-Garcia · 2010 · Cell Cycle
  98. Induction of Tolerance by Porphyromonas gingivalis on APCs: a Mechanism Implicated in Periodontal Infection
    Nicolas Cohen, J. Morisset, Dominique Émilie · 2004 · Journal of Dental Research
  99. Immune checkpoint blockade reveals the stimulatory capacity of tumor-associated CD103 + dendritic cells in late-stage ovarian cancer
    Dallas B. Flies, Tomoe Higuchi, Jaryse C. Harris, Vibha Jha, Phyllis A. Gimotty, Sarah Foster Adams · 2016 · OncoImmunology
  100. High-affinity human PD-L1 variants attenuate the suppression of T cell activation
    Zhaoduan Liang, Ye F. Tian, Wenxuan Cai, Zhiming Weng, Yanyan Li, Huanling Zhang, Yifeng Bao, Yi Li · 2017 · Oncotarget